Hypofractionation/Ultra-hypofractionation for Prostate Cancer Radiotherapy

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Prostate cancer is the most common cancer diagnosed globally in men.
• Radiotherapy is a key treatment for localized prostate cancer.
• Prostate cancer's radiobiological characteristics favor hypofractionation.

Purpose of the Study:

• To evaluate the efficacy and safety of hypofractionated radiotherapy for prostate cancer.
• To explore the benefits of ultra-hypofractionation, including SBRT.
• To assess the impact of these techniques on resource utilization in radiation oncology.

Main Methods:

• Comparison of hypofractionation and conventional fractionation schedules.
• Analysis of biochemical control rates and toxicity profiles.
• Review of stereotactic body radiotherapy (SBRT) outcomes for ultra-hypofractionation.

Main Results:

• Hypofractionation is noninferior to conventional fractionation with acceptable toxicity.
• Ultra-hypofractionation (SBRT) demonstrates high biochemical control rates and low late toxicity.
• Hypofractionated schedules improve resource utilization without sacrificing patient safety or treatment efficacy.

Conclusions:

• Hypofractionated and ultra-hypofractionated radiotherapy are effective and safe options for localized prostate cancer.
• These advanced techniques optimize resource use in radiation oncology.
• Future research focuses on refining patient selection, fractionation, and incorporating advanced technologies for improved outcomes.